Policy & Regulation
Circio and Avenue Biosciences launch research collaboration to improve protein secretion for gene therapy
16 July 2026 - Circio Holding ASA (OSE:CRNA), a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, said on Thursday that it has entered into a researc...
Valerio Therapeutics signs R&D collaboration with Abivax and outlines pipeline milestones
16 July 2026 - Biotechnology company Valerio Therapeutics (Euronext Growth Paris:ALVIO) on Thursday announced a binding term sheet with Abivax for an exclusive global research and development collabor...
Lakewood-Amedex Biotherapeutics reports positive Nu-3 Gel preclinical safety data for upcoming Phase 2a trial
16 July 2026 - Clinical-stage biotechnology company Lakewood-Amedex Biotherapeutics Inc (NASDAQ:LABT) on Wednesday announced preclinical safety data for its Nu-3 gel formulation that establishes a str...
MAXONA Pharmaceuticals' Phase 2 clinical trial IND application for MAX-001 cleared by US FDA
16 July 2026 - Clinical-stage pharmaceutical company MAXONA Pharmaceuticals announced on Wednesday that the US Food and Drug Administration (FDA) has cleared the company's Investigational New Dru...
Kalohexis presents dual MC3R/MC4R activation data at ICO 2026
16 July 2026 - Clinical-stage biotechnology company Kalohexis Inc announced on Wednesday that data supporting dual melanocortin-3 receptor/melanocortin-4 receptor (MC3R/MC4R) activation as a novel mec...
Merck reports positive Phase 3 results for KEYTRUDA in advanced endometrial cancer
15 July 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Wednesday that its Phase 3 KEYNOTE-C93 trial evaluating KEYTRUDA (pembroliz...